title: A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
abstract: BACKGROUND
  Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States.
  
  
  METHODS
  Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States. Patients with nodal PTCL and completed records regarding baseline characteristics and initial therapy were included in this analysis. All statistical tests were 2-sided.
  
  
  RESULTS
  Of a total of 499 patients enrolled, 256 (51.3%) had nodal PTCL and completed treatment records. As initial therapy, patients received doxorubicin-containing regimens (41.8%), regimens containing doxorubicin plus etoposide (20.9%), other etoposide regimens (15.8%), other single-agent or combination regimens (19.2%), and gemcitabine-containing regimens (2.1%). Survival was found to be statistically significantly longer for patients who received doxorubicin (log-rank P = .03). After controlling for disease histology and International Prognostic Index, results demonstrated a trend toward significance in mortality reduction in patients who received doxorubicin compared with those who did not (hazard ratio, 0.71; 95% confidence interval, 0.48-1.05 [P = .09]).
  
  
  CONCLUSIONS
  To the authors' knowledge, there is no clear standard of care in the treatment of patients with PTCL in the United States. Although efforts to improve frontline treatments are necessary, anthracyclines remain an important component of initial therapy for curative intent. Cancer 2017;123:1174-1183. © 2016 American Cancer Society.
authors.affiliation: Research Service, St Louis Veterans Affairs Medical Center, St. Louis, Missouri.|Department of Medical Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Carson
authors.affiliation: Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Horwitz
authors.affiliation: Department of Medicine, University of California at Irvine, Irvine, California.
authors.forename: Lauren C
authors.initials: LC
authors.lastname: Pinter-Brown
authors.affiliation: Provost and Chief Scientific Officer, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
authors.forename: Steven T
authors.initials: ST
authors.lastname: Rosen
authors.affiliation: Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.affiliation: Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
authors.forename: Eric D
authors.initials: ED
authors.lastname: Hsi
authors.affiliation: Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Federico
authors.affiliation: Department of Hematology-Oncology, Hôpital Saint Louis, Paris, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
authors.affiliation: MedNet Solutions, Minnetonka, Minnesota.
authors.forename: Marc
authors.initials: M
authors.lastname: Schwartz
authors.affiliation: MedNet Solutions, Minnetonka, Minnesota.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Bellm
authors.affiliation: Research and Development, Spectrum Pharmaceuticals Inc, Irvine, California.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Acosta
authors.affiliation: Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors.forename: Andrei R
authors.initials: AR
authors.lastname: Shustov
authors.affiliation: Department of Medicine, Stanford University Medical Center, Stanford, California.
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.affiliation: Department of Hematology/Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
authors.forename: Tatyana A
authors.initials: TA
authors.lastname: Feldman
authors.affiliation: Department of Hematology and Oncology, Emory University, Atlanta, Georgia.
authors.forename: Mary Jo
authors.initials: MJ
authors.lastname: Lechowicz
authors.affiliation: Department of Medicine, University of Chicago, Chicago, Illinois.
authors.forename: Sonali M
authors.initials: SM
authors.lastname: Smith
authors.affiliation: Department of Medicine, Dartmouth Hitchcock Medical Center, Hanover, New Hampshire.
authors.forename: Frederick
authors.initials: F
authors.lastname: Lansigan
authors.affiliation: Department of Medicine, University of Southern California, Los Angeles, California.
authors.forename: Anil
authors.initials: A
authors.lastname: Tulpule
authors.affiliation: Department of Medicine, West Virginia University, Morgantown, West Virginia.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Craig
authors.affiliation: Department of Hematology, Vanderbilt University, Nashville, Tennessee.
authors.forename: John P
authors.initials: JP
authors.lastname: Greer
authors.affiliation: Department of Medical Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
authors.affiliation: Minnesota Oncology, Virginia Piper Cancer Institute, Minneapolis, Minnesota.
authors.forename: Joseph W
authors.initials: JW
authors.lastname: Leach
authors.affiliation: Overlook Medical Center, Summit, New Jersey.
authors.forename: Neil
authors.initials: N
authors.lastname: Morganstein
authors.affiliation: Department of Medicine, University of Rochester, Rochester, New York.
authors.forename: Carla
authors.initials: C
authors.lastname: Casulo
authors.affiliation: Department of Internal Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
authors.forename: Steven I
authors.initials: SI
authors.lastname: Park
authors.affiliation: Department of Medical Oncology, Yale University, New Haven, Connecticut.
authors.forename: Francine M
authors.initials: FM
authors.lastname: Foss
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019468:Disease Management; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D011446:Prospective Studies; D018426:SEER Program; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
keywords: T cell; anthracyclines; cohort studies; drug therapy; lymphoma; peripheral; prospective studies; treatment outcome